Research Paper

Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population

Ajay Sharma1, Paula J. Alvarez2, Steven D. Woods2, Jeanene Fogli2 and Dingwei Dai1,*

1Healthagen, an affiliate of Aetna Inc., part of the CVS Health family of companies, New York, NY, USA
2Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA

*Correspondence: Dingwei Dai, Healthagen, part of the CVS Health family of companies, 100 Park Ave, New York, NY 10017, USA. Tel: +1-212-457-0603; Email: Dingwei.Dai@healthagen.com

Received March 13, 2020; Accepted October 19, 2020.

Abstract

Background Hyperkalemia is a serious metabolic condition and can lead to life-threatening cardiac arrhythmias and sudden death. Guideline-directed medications that affect the renin-angiotensin-aldosterone axis can increase serum potassium and may limit their use. Hyperkalemia has been shown to drive healthcare resource utilization (HRU) and costs for patients with cardiorenal conditions.

Objectives To describe hyperkalemic patient characteristics and quantify patient HRU and costs relative to normokalemic patients from a large US health plan.

Methods A retrospective cohort study that identified and evaluated a hyperkalemic patient population from a large administrative claims database. The observation period was 1 January 2015 to 31 May 2018, with a 1-year follow-up period after the index date (the earliest service/claim with evidence of hyperkalemia). Primary patient outcomes included inpatient admissions, emergency department (ED) visits, primary care physician (PCP)/specialist visits, length of stay (LOS) and associated medical and pharmacy costs. This hyperkalemic cohort was stratified by renin-angiotensin-aldosterone system inhibitor (RAASI) utilization and chronic kidney disease (CKD) stage for the economic analysis.

Key findings 86,129 adult patients with hyperkalemia were evaluated in the study cohort (median age: 69 years). There were more males [45,155 (52%)], with the majority of patients located in the Southern United States [45,541 (51%)] and a 70/30 split of Medicare to a commercial health plan. Most patients had CKD, hypertension and hyperlipidemia; ≥80% of the patients had ≥4 comorbidities. Over 40% of patients were not receiving RAASI therapy, and potassium binder use was low (<5%). Patients using optimal-dose RAASI with proportion of days covered ≥80% were observed to have the lowest HRU for inpatient admissions, ED and PCP visits and LOS days.

Conclusions Hyperkalemia is associated with substantial HRU and costs. The development of a quality improvement program structured around the management of hyperkalemia in individuals with heart failure, diabetes and/or CKD may be necessary.

Keywords: health economics; pharmaco-economics; managed care; outcomes research; quality of care; hyperkalemia
Introduction

Hyperkalemia is a common electrolyte abnormality that can be severe and life threatening. An estimated 3.7 million US adults had an episode of hyperkalemia in 2014. About half of all patients with hyperkalemia have either chronic kidney disease (CKD) and/or heart failure (HF), and the annual prevalence of hyperkalemia in this population was 6.35%.

The management and prevention of hyperkalemia requires a multidisciplinary approach that entails reducing intake of high potassium foods, adjusting hyperkalemia-inducing medications and adding medications that reduce the plasma potassium concentration. Hyperkalemia is associated with both clinical and economic consequences, including increased emergency department (ED) visits, hospitalizations and mortality. These have a direct bearing on the overall cost of managing patients, especially in a managed care setting.

Patients with CKD may be predisposed to hyperkalemia for a variety of reasons. Principal causes include patients’ impaired glomerular filtration rate combined with a frequently high dietary potassium intake relative to residual renal function, a commonly observed extracellular shift of potassium caused by the metabolic acidosis of renal failure. Other disease states and therapies that place patients at increased risk for hyperkalemia include diabetes, HF and use of renin-angiotensin aldosterone system inhibitor (RAASI) therapy, which includes angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, direct renin inhibitors and mineralocorticoid-receptor antagonists. Randomized clinical trials have demonstrated that RAASI therapy can reduce the risk of death and slow the disease progression in patients with HF, CKD and diabetes. Increased serum potassium is a common electrolyte change associated with medications that affect the renin-angiotensin-aldosterone axis, limiting their use.

Hyperkalemia drives healthcare resource utilization (HRU) and costs for patients with cardiorenal conditions. In 2011, the estimated total annual hospital charges for Medicare admissions with hyperkalemia as the primary diagnosis were approximately $697 million (US). In 2014, there was an estimated $1.2 billion in total annual hospital charges for patients admitted with a primary diagnosis of hyperkalemia, with an average length of stay (LOS) of 3.3 days and mean charges of $29,181 per stay. Collectively, these factors speak to the potential clinical and economic value of hyperkalemia management in individuals with HF and/or CKD.

Patients who are prescribed and tolerate RAASI therapy at maximum recommended doses have been observed to have lower rates of adverse outcomes/death and incur lower total costs compared with patients prescribed submaximum doses across disease cohorts (HF, CKD and diabetes) and payers (Medicare and commercial insurance). The goal of this study was to describe the characteristics of hyperkalemic patients and quantify HRU and costs relative to normokalemic patients using data from a large US health plan. Comorbid conditions and multiple comorbidity patterns among hyperkalemic patients were also assessed.

Methods

Study design

A retrospective cohort study identified and evaluated patients with hyperkalemia from a large administrative claims database from 1 January 2015 to 31 May 2017. The observation period was 1 January 2015 to 31 May 2018, including a 1-year follow-up period after the index date (defined as the earliest service/claim with evidence of hyperkalemia). This cohort was stratified by RAASI therapy utilization and CKD stage for the economic analysis. All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations. As this study used only statistically de-identified patient records, it was exempted from institutional review board approval.

Patient selection

Individuals were included in this study if they were aged ≥18 years and enrolled in an Aetna fully insured commercial health plan or Medicare Advantage health plan with medical and pharmacy benefits for at least 12 months after the index date. Medical and/or pharmacy claims and laboratory results with service dates from 1 January 2015 to 31 May 2017 were used to identify the hyperkalemic population. Qualifying criteria were:

1. Two or more potassium lab tests >5.0 mEq/L on different dates (via Logical Observation Identifiers Names and Codes (LOINC; Supplementary Table S1);
2. OR Two or more diagnosis codes of hyperkalemia (ICD-9-CM code of 276.7 or one ICD-10-CM code of E87.5);
3. OR One diagnosis code of hyperkalemia and one lab potassium value >5.0 mEq/L;
4. OR Evidence of a National Drug Code number for either patiromer or sodium polystyrene sulfonate (SPS; Figure 1).

Statistical analyses

Means, standard deviations and medians were reported for continuous variables, and frequencies (percentages) were reported for categorical variables. Comparisons of patient characteristics and outcomes between patients with and without RAASI therapy were performed using the chi-square test (categorical variables) and the Wilcoxon rank-sum test (continuous variables). Multicomorbidities were measured by the number of comorbidities. To evaluate sensitivity of the cutoff point of blood potassium level >5.0 mEq/L for hyperkalemia, a sensitivity analysis was conducted to examine the total healthcare costs using >5.0 to 5.5, >5.5 to 6.0 and >6.0 mEq/L compared with CKD patients with normokalemia. We also performed subgroup analyses to assess the economic impact of hyperkalemia in patients with diabetes and HF. All data management and statistical analyses were conducted using SAS version 9.4 statistical software (SAS Institute Inc., Cary, NC, USA). All P values were two-sided, with P < 0.05 considered statistically significant.

Primary endpoints

The primary patient outcomes evaluated in this study included inpatient admissions, ED visits, primary care physician (PCP) visits, specialist visits, LOS and associated medical and pharmacy costs.
patients. The majority of patients had CKD (n = 79,084; 92%), hypertension (n = 70,146; 81%) and hyperlipidemia (n = 68,532; 80%). At least 80% of the study population had ≥4 comorbidities. Over 40% of patients (n = 35,536) were not receiving RAASi therapy, including diabetic (n = 11,088) and HF (n = 6479) patients.

Of the patients using RAASi therapy (n = 50,593), approximately 17% (8461) were using the optimal dose with proportion of days covered (PDC) ≥80%. These patients were observed to have the lowest HRU for inpatient admissions (n = 1783; 21%), ED visits (n = 2267; 27%), PCP visits (n = 6983; 83%) and LOS days (n = 1.70; 6%; Table 2).

The total healthcare costs [per member per year (PMPY)] by CKD stage [normokalemia (potassium 3.8–5.0 mEq/L) vs. hyperkalemia] 1-year post-index date are given in Figure 2. On average, hyperkalemic patients were more than twice as costly ($20,029) as patients with normal serum potassium ($8570). Nominal (≤5%) potassium binder therapy (patiromer/SPS) use was observed in these hyperkalemic patients (Figure 3).

Figure 4 shows the total mean costs (PMPY) for patients both utilizing and not utilizing RAASi therapy. In the RAASi group, total costs (PMPY) were $25,340, whereas the no-RAASi group observed a cost of $26,412. When evaluating patients receiving optimal and suboptimal RAASi doses with a PDC <80%, the total mean costs were $32,739 and $32,831, respectively (Figure 5). In patients with a PDC ≥80%, each group observed lower overall costs, whereas the suboptimal dose showed marginally increased costs [$20,435 and $19,529 (suboptimal RAASi and optimal RAASi dose, respectively)].

The sensitivity analyses showed that the total mean costs (PMPY) increased remarkably by blood potassium level (Supplementary Figure S1). Patients with potassium levels >5.0 mEq/L on different dates or ≥2 diagnosis codes of hyperkalemia (ICD-9-CM 276.7/ICD-10-CM E87.5) OR ≥1 diagnosis code of hyperkalemia and 1 potassium laboratory test >5.0 mEq/L OR 1 prescription of either SPS or patiromer.

Supplementary Figure S2 shows that hyperkalemic patients without diabetes and HF had the lowest costs ($16,836 PMPY) compared to hyperkalemic patients with diabetes, HF, or both diabetes and HF ($21,451, $35,303 and $46,286 PMPY, respectively).

Discussion

This retrospective cohort study used administrative claims data to construct a large, comprehensive cohort of patients diagnosed with hyperkalemia to profile patients based on demographics, comorbidities, HRU and costs. There are limited published studies characterizing the economic burden of hyperkalemia. A study by Dunn et al. in 2015 identified a mean inpatient cost of $24,178 per episode and an average LOS of 3.2 days among patients admitted from EDs to hospitals for elevated potassium levels. In a retrospective database study by Betts et al., patients with hyperkalemia had significantly higher HRU and healthcare costs compared with matched controls. Those with hyperkalemia incurred approximately $4100 more in total healthcare costs over 30 days ($5994 vs. $1865) and approximately $16,000 more in total healthcare costs over 1 year ($31,844 vs. $15,861). Our current study showed that hyperkalemia is associated with substantial HRU and healthcare costs. CKD patients with hyperkalemia utilized more healthcare resources and incurred on average more than twice the healthcare costs of CKD patients without hyperkalemia ($20,029 vs. $8570 annually). More specifically, patients with hyperkalemia and stage 5 CKD receiving dialysis had an observed total cost of $67,758, while normokalemic dialysis patients incurred $37,094. This is also consistent with a study by Polson et al., which showed that hyperkalemic patients with CKD, HF or both CKD and HF had higher overall costs.

Older patients with an advanced stage of CKD, diabetes and/or HF are at higher risk for hyperkalemia. In our study, hyperkalemic patients without diabetes and HF observed lower costs than hyperkalemic patients with diabetes or HF (Supplementary Figure S2). The highest costs were observed in hyperkalemic patients with...
| Characteristics | Overall | RAASi use | No RAASi | P value |
|-----------------|---------|-----------|----------|---------|
| Age             | N = 86,129 | n = 50,593 (58.74%) | n = 35,536 (41.26%) | <0.0001 |
| Age (Mean, SD)  | 67.48 (13.43) | 69.36 (11.75) | 64.81 (15.11) | <0.0001 |
| Gender, n (%)   | Male: 45,155 (52.43) | 27,514 (54.38) | 17,641 (49.64) | <0.0001 |
|                | Female: 40,972 (47.57) | 23,078 (45.62) | 17,894 (50.35) | <0.0001 |
| Geographic region, n (%) | Midwest: 14,955 (17.37) | 9346 (18.48) | 5609 (15.79) | <0.0001 |
|                | Northeast: 22,775 (26.46) | 13,324 (26.35) | 9451 (26.61) | <0.0001 |
|                | South: 45,541 (50.58) | 25,294 (50.02) | 18,247 (51.37) | <0.0001 |
| Urban-rural, n (%) | Urban: 36,029 (41.83) | 20,678 (40.87) | 15,351 (43.20) | <0.0001 |
|                | Rural: 28,164 (32.70) | 17,037 (33.67) | 11,127 (31.31) | <0.0001 |
| Median household income ($) | Mean: 61,136 (22,523) | 59,909 (21,832) | 62,883 (23,360) | <0.0001 |
|                | Median (interquartile range): 61,136 (45,037–73,308) | 55,269 (44,469–71,913) | 57,306 (45,581–76,471) | <0.0001 |
| Line of business, n (%) | Commercial: 25,218 (29.28) | 11,667 (23.06) | 13,551 (38.13) | <0.0001 |
|                | Medicare: 60,911 (70.27) | 38,926 (76.94) | 21,985 (61.87) | <0.0001 |
| Retrospective ERG risk scores | Mean: 4.50 (6.39) | 4.68 (6.20) | 4.24 (6.64) | <0.0001 |
|                | Median (interquartile range): 4.50 (2.35–6.74) | 4.68 (2.69–6.15) | 4.24 (2.47–5.18) | <0.0001 |
| Number of comorbid conditions | Mean: 7.32 (3.89) | 8.05 (3.64) | 6.29 (4.01) | <0.0001 |
|                | Median (interquartile range): 7.32 (4–10) | 8 (5–10) | 6 (3–9) | <0.0001 |
| Comorbid condition | CKD any: 79,084 (91.82) | 49,098 (92.72) | 32,179 (90.54) | <0.0001 |
|                | CKD stage 1: 8632 (10.02) | 3413 (6.75) | 5127 (14.68) | <0.0001 |
|                | CKD stage 2: 27,471 (31.90) | 14,349 (28.36) | 13,122 (36.93) | <0.0001 |
|                | CKD stage 3: 28,07 (35.34) | 20,46 (40.46) | 8,004 (22.13) | <0.0001 |
|                | CKD stage 4: 8164 (9.48) | 5578 (11.03) | 2586 (7.28) | <0.0001 |
|                | CKD stage 5: 5328 (6.19) | 2704 (5.34) | 2624 (7.38) | <0.0001 |
|                | CKD unspecified: 682 (0.79) | 393 (0.78) | 289 (0.81) | <0.0001 |
| Hypertension    | 70,146 (81.44) | 49,098 (92.72) | 32,179 (90.54) | <0.0001 |
|                | CKD: 79,084 (91.82) | 46,908 (92.72) | 32,176 (90.54) | <0.0001 |
|                | Resistant hypertension*: 592 (0.69) | 429 (0.85) | 163 (0.46) | <0.0001 |
| Hyperlipidemia  | 68,532 (79.57) | 44,267 (87.50) | 24,268 (68.28) | <0.0001 |
| Diabetes mellitus| 41,181 (47.81) | 30,093 (59.48) | 11,088 (31.20) | <0.0001 |
| Ischemic heart disease | 24,336 (28.26) | 16,879 (33.67) | 7457 (20.98) | <0.0001 |
| Heart failure   | 22,123 (25.69) | 15,644 (30.92) | 6479 (18.23) | <0.0001 |
| Medications     | RAASi | MRAs: 5033 (5.84) | 5033 (9.95) | 0 | - |
|                | ACEis | 32,228 (37.42) | 32,228 (63.70) | 0 | - |
|                | ARBs | 18,745 (21.76) | 18,745 (35.05) | 0 | - |
|                | Direct renin inhibitors | 50 (0.06) | 50 (0.10) | 0 | - |
|                | Potassium binders | 3638 (4.22) | 2061 (4.07) | 0 | - |
|                | NSAIDs | 15,944 (18.51) | 9258 (18.30) | 6686 (18.81) | 0.0554 |
|                | Calcineurin inhibitors | 1145 (1.33) | 530 (1.05) | 615 (1.73) | <0.0001 |
|                | Potassium-sparing diuretics | 1107 (1.29) | 751 (1.48) | 356 (1.00) | <0.0001 |
|                | Diurexin | 1896 (2.20) | 1391 (2.75) | 505 (1.42) | <0.0001 |
|                | Beta-blocker | 28,939 (33.60) | 19,182 (37.91) | 9757 (27.46) | <0.0001 |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ERG, episode risk group; MRA, mineralocorticoid-receptor antagonist; NSAID, non-steroidal anti-inflammatory drug.

*Resistant hypertension was identified by >1 claims with ICD-9/ICD-10 (997.91, I16.0, I16.1, I16.9) at least 7 days apart.

Both diabetes and HF (Supplementary Figure S2), These findings are similar to the study by Betts et al. that reported a significant economic burden associated with hyperkalemic patients with comorbidities.[13] Treatment with RAASi agents has been shown to reduce morbidity and mortality in patients with CKD, HF or both, and treatment guidelines recommend the use of these medications at optimal...
doses to manage these patients. This analysis found a significant percentage CKD patients with cardiorenal comorbidities are not receiving guideline-directed medical therapies, revealing an important opportunity to improve treatment. In our study, we observed that only 26% of patients received an optimal dose of their RAASi medication. Of these patients, 64% achieved a PDC ≥80%. When evaluating this patient profile (optimal-dose RAASi and PDC ≥80%), there was an observed decrease in inpatient admissions, ED visits and PCP/specialist visits. These results are consistent with the findings of a study by Epstein et al., which demonstrated...
that patients receiving RAASi therapies at maximum doses incurred lower total costs than patients prescribed RAASi therapies at submaximum doses.[11]

Managing hyperkalemia in patients with cardiorenal diseases poses a challenge for clinicians. Electing to not use RAASi treatment in this patient population may lead to poor health outcomes and increased healthcare costs. One option for meeting this challenge is chronic treatment of hyperkalemia with contemporary potassium binders such as patiromer and sodium zirconium cyclosilicate. The consistency of results across prospective clinical trials supports the chronic use of novel potassium binders up to 1 year. [5, 15] However, we observed that potassium-binder therapy continues to be underutilized with only 4.4% of patients prescribed a binder during the study period.

Limitations
This is a descriptive observational study; therefore, no causal relationships can be derived. We have assumed that patients were taking the medications that were dispensed. The identification of hyperkalemia depended in part on the serum potassium laboratory data. It is possible that some laboratory tests performed were not present in the claims data. For example, tests done in hospitals or ED visits would be bundled in ED visit or inpatient claims. However, these patients would be identified using ICD-9-CM or ICD-10-CM codes from the claims data. Comorbidities were identified using ICD-9-CM and ICD-10-CM codes, which are used for administrative purposes. As a result, certain comorbidities may be underestimated.

Conclusions
Hyperkalemia is associated with substantial HRU and healthcare costs and remains a significant healthcare burden. In this study, patients with hyperkalemia were more likely to be hospitalized, visit the ED or see a PCP or specialist as an outpatient. The development of a quality improvement program structured around the management of hyperkalemia in individuals with CKD, HF and/or diabetes may be necessary to optimize RAAS inhibitor treatment and reduce costs.

Supplementary Material
Supplementary data are available at Journal of Pharmaceutical Health Services Research online.

Acknowledgement
Editorial support was provided by Lauren Burawski MA and Impact Communication Partners, Inc.
Funding
This work was supported by Relypsa, Inc., a Vifor Pharma Group Company.

Author Contributions
All authors fully contributed to the content of this manuscript, including meeting the four criteria of the Internal Committee of Medical Journal Editors. All authors had full access to all of the data in the study and take full responsibility for the integrity of the work and the accuracy of the data analysis, from inception to published article.

Conflict of Interest
A.S. reports serving as a clinical investigator for and employment by Healtheagen, an affiliate of Aetna Inc., part of the CVS Health family of companies, New York, NY, which conducted research funded by Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA. P.J.A., S.D.W., and J.F. report employment by Relypsa, Inc., a Vifor Pharma Group Company, and stock in Vifor Pharma, Glattbrugg, Switzerland. D.D. reports serving as a lead scientist for and employment by Healtheagen, an affiliate of Aetna Inc., part of the CVS Health family of companies, New York, NY, which conducted research funded by Relypsa, Inc., a Vifor Pharma Group Company.

References
1. Chang AR, Sang Y, Leddy J et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 2016; 67: 1181–8. https://doi.org/10.1161/HYPERTENSIONAHA.116.07363
2. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9. https://doi.org/10.1056/NEJMoa011161
3. Betts KA, Woolley JM, Mu F et al. The prevalence of hyperkalemia in the United States. Curr Med Res Opin 2018; 34: 971–8. https://doi.org/10.1080/03007995.2018.1433141
4. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med 2017; 84: 934–42. https://doi.org/10.3949/ccjm.84a.17056
5. Bakris GL, Pitt B, Weir MR et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease; the AMETHYST-DN randomized clinical trial. JAMA 2015; 314: 151–61. https://doi.org/10.1001/jama.2015.7446
6. Dunn JD, Benton WW, Orozco-Torrentera E et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care 2015; 21: S307–15.
7. Einhorn LM, Zhan M, Hsu VD et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156–62. https://doi.org/10.1001/archinternmed.2009.132
8. Kovacs CP,Rowan CG, Conrad A et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep 2019; 4: 301–9. https://doi.org/10.1016/j.ekir.2018.10.020
9. Lewis EF, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60. https://doi.org/10.1056/NEJMoa0111303
10. Polson M, Lord TC, Kangethe A et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm 2017; 23: S2–9. https://doi.org/10.18553/jmcp.2017.23.4-a.s2a
11. Epstein M, Alvarez PJ, Reaven NL et al. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2016; 22: S311–24.
12. Epstein M, Reaven NL, Funk SE et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015; 21: S212–20.
13. Betts KA, Woolley JM, Mu F et al. The cost of hyperkalemia in the United States. Kidney Int Rep 2018; 3: 385–93. https://doi.org/10.1016/j.ekir.2017.11.003
14. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–290.
15. Spinhoven B,Fishbane S, Pergola PE et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol 2019; 14: 798–809. https://doi.org/10.2215/CJN.12651018